Grimes & Company, Inc. Adma Biologics, Inc. Transaction History
Grimes & Company, Inc.
- $3.58 Billion
- Q2 2025
A detailed history of Grimes & Company, Inc. transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Grimes & Company, Inc. holds 13,674 shares of ADMA stock, worth $225,894. This represents 0.01% of its overall portfolio holdings.
Number of Shares
13,674
Previous 21,690
36.96%
Holding current value
$225,894
Previous $430,000
42.09%
% of portfolio
0.01%
Previous 0.01%
Shares
11 transactions
Others Institutions Holding ADMA
# of Institutions
393Shares Held
190MCall Options Held
2.53MPut Options Held
696K-
Black Rock Inc. New York, NY18.6MShares$308 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA16.8MShares$278 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA12.9MShares$213 Million0.05% of portfolio
-
State Street Corp Boston, MA11.4MShares$189 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA5.91MShares$97.7 Million0.01% of portfolio
About ADMA BIOLOGICS, INC.
- Ticker ADMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 196,356,992
- Market Cap $3.24B
- Description
- ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...